These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22622020)

  • 1. Analyzing global trends of biomarker use in drug interventional clinical studies.
    Hayashi K; Masuda S; Kimura H
    Drug Discov Ther; 2012 Apr; 6(2):102-7. PubMed ID: 22622020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors.
    Ichimaru K; Toyoshima S; Uyama Y
    Clin Pharmacol Ther; 2010 Mar; 87(3):362-6. PubMed ID: 20107436
    [No Abstract]   [Full Text] [Related]  

  • 3. [Infrastructure for new drug development to treat muscular dystrophy: current status of patient registration (remudy)].
    Nakamura H; Kimura E; Kawai M
    Brain Nerve; 2011 Nov; 63(11):1279-84. PubMed ID: 22068481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers in Alzheimer's disease drug development.
    Cummings JL
    Alzheimers Dement; 2011 May; 7(3):e13-44. PubMed ID: 21550318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current and future views from pharmaceutical industry perspectives on development of antidepressants].
    Arano I; Imaeda T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Aug; 31(4):181-6. PubMed ID: 21941853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications of 'decisionable' biomarkers in cardiovascular drug development.
    Krishna R; Wagner JA
    Biomark Med; 2010 Dec; 4(6):815-27. PubMed ID: 21133701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of industry sponsorship to published outcomes in gastrointestinal clinical research.
    Brown A; Kraft D; Schmitz SM; Sharpless V; Martin C; Shah R; Shaheen NJ
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1445-51. PubMed ID: 17101295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sponsorship and design characteristics of trials registered in ClinicalTrials.gov.
    Roumiantseva D; Carini S; Sim I; Wagner TH
    Contemp Clin Trials; 2013 Mar; 34(2):348-55. PubMed ID: 23380028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of mechanistic biomarkers for evaluating investigational CNS compounds in early drug development.
    Soares HD
    Curr Opin Investig Drugs; 2010 Jul; 11(7):795-801. PubMed ID: 20571975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performing phase I clinical trials of anticancer agents: perspectives from within the European union and Japan.
    Forster MD; Saijo N; Seymour L; Calvert H
    Clin Cancer Res; 2010 Mar; 16(6):1737-44. PubMed ID: 20215555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approaches to Japanese dose evaluation in global drug development: factors that generate different dosages between Japan and the United States.
    Nakashima K; Narukawa M; Takeuchi M
    Clin Pharmacol Ther; 2011 Dec; 90(6):836-43. PubMed ID: 22048222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
    Dancey JE; Dobbin KK; Groshen S; Jessup JM; Hruszkewycz AH; Koehler M; Parchment R; Ratain MJ; Shankar LK; Stadler WM; True LD; Gravell A; Grever MR;
    Clin Cancer Res; 2010 Mar; 16(6):1745-55. PubMed ID: 20215558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantifying the usefulness of PD biomarkers in Phase 2 screening trials of oncology drugs.
    Holmgren E
    Stat Med; 2008 Oct; 27(24):4928-38. PubMed ID: 18618429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of the European Clinical Trials Directive on published drug research in anaesthesia.
    Walker E; Hankins MC; White SM
    Anaesthesia; 2009 Sep; 64(9):984-9. PubMed ID: 19686484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical considerations for the next generation of clinical trials.
    Wu W; Shi Q; Sargent DJ
    Semin Oncol; 2011 Aug; 38(4):598-604. PubMed ID: 21810519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug safety sciences and the bottleneck in drug development.
    Watkins PB
    Clin Pharmacol Ther; 2011 Jun; 89(6):788-90. PubMed ID: 21593756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of biomarker usage on oncology drug development.
    Hayashi K; Masuda S; Kimura H
    J Clin Pharm Ther; 2013 Feb; 38(1):62-7. PubMed ID: 23057528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outsourcing clinical trials.
    Nicholas J
    J Natl Cancer Inst; 2012 Jul; 104(14):1043-5. PubMed ID: 22781429
    [No Abstract]   [Full Text] [Related]  

  • 19. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From biomarker strategies to biomarker activities and back.
    van Gool AJ; Henry B; Sprengers ED
    Drug Discov Today; 2010 Feb; 15(3-4):121-6. PubMed ID: 19931413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.